Skip to main
  1. Stocks
  2. MapLight Therapeutics Inc
  3. Forecast
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 64%
Buy 18%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics is attractive because its lead asset ML-007C-MA has already shown a differentiated signal in schizophrenia, including a 4.5-point placebo-adjusted PANSS improvement at week 5, a Cohen’s d of 0.37, and prespecified cognitive benefit with a tolerability profile that appears more convenient than Cobenfy. The bigger fundamental upside is the much larger Alzheimer’s disease psychosis opportunity, where there are no approved therapies and the same mechanism could translate into a cleaner, bid-dosed, safety-focused alternative that addresses a meaningful unmet need in an older population. Financially, the company reported a ~$501M pro forma cash position and a $150M PIPE, which management says funds VISTA and ZEPHYR through 2028, giving it enough runway to reach key readouts in 2027 without near-term financing pressure.

Bears say

MapLight Therapeutics is a late-stage follower in a contested muscarinic schizophrenia market, where ZEPHYR only modestly beat placebo on PANSS total (−4.5, ES 0.37, p=0.015) while the QD arm missed, negative symptoms missed, and active-arm discontinuations were 19.9% with notable nausea and vomiting. Its differentiation versus Cobenfy appears limited to food flexibility and convenience, not superior efficacy, so the commercial thesis looks thin as an approved incumbent and multiple competitors already crowd the class. With a required additional Phase 3 study and potential extra QD work, the company’s sales outlook was cut to about $400mn in schizophrenia and $2bn in ADP in 2037E, underscoring execution, approval, and financing risk.

MPLT has been analyzed by 11 analysts, with a consensus rating of Buy. 64% of analysts recommend a Strong Buy, 18% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

MPLT Analyst Forecast & Price Prediction

Get the latest MPLT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MPLT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Buy based on their latest research and market trends.

According to 11 analysts, MPLT has a Buy consensus rating as of Nov 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


MPLT Analyst Forecast & Price Prediction

Get the latest MPLT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MPLT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MPLT stock data and trends